CompletedNCT02717195
Lu AF35700 for Treatment-Resistant Schizophrenia Symptoms
About this title
Read the official source — NCT02717195Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Bellflower and 146 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,098
- Sponsor
- H. Lundbeck A/S
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, Bulgaria, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT02717195
- Official title
Show the full official title
Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bellflower, United States · Cerritos, United States · Costa Mesa, United States
110 more locations
- Culver City, United States
- Garden Grove, United States
- Glendale, United States
- National City, United States
- Oceanside, United States
- Orange, United States
- San Bernardino, United States
- Santa Ana, United States
- Sherman Oaks, United States
- Torrance, United States
- Washington D.C., United States
- Bradenton, United States
- Jacksonville, United States
- Miami, United States
- North Miami, United States
- Oakland Park, United States
- Orange City, United States
- Tampa, United States
- Atlanta, United States
- Decatur, United States
- Chicago, United States
- Hoffman Estates, United States
- Shreveport, United States
- Flowood, United States
- Las Vegas, United States
- Berlin, United States
- Marlton, United States
- Glen Oaks, United States
- Jamaica, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Charlotte, United States
- Hickory, United States
- Norristown, United States
- Charleston, United States
- Austin, United States
- Dallas, United States
- Fort Worth, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Pazardzhik, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Tserova Koria, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Chatham, Canada
- Kingston, Canada
- Montreal, Canada
- Penticton, Canada
- Québec, Canada
- Brno, Czechia
- Hostivice, Czechia
- Lnáře, Czechia
- Prague, Czechia
- Pärnu, Estonia
- Tallinn, Estonia
- Viljandi, Estonia
- Espoo, Finland
- Kuopio, Finland
- Turku, Finland
- Durango, Mexico
- Guadalajara, Mexico
- México, Mexico
- Monterrey, Mexico
- San Luis Potosí City, Mexico
- Bełchatów, Poland
- Bialystok, Poland
- Gorlice, Poland
- Lodz, Poland
- Lublin, Poland
- Pruszcz Gdański, Poland
- Pruszków, Poland
- Torun, Poland
- Wroclaw, Poland
- Bucharest, Romania
- Campulung Muscel, Romania
- Sibiu, Romania
- Târgu Mureş, Romania
- Nikol’skoye, Russia
- Arkhangelsk, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Yaroslavl, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Bratislava, Slovakia
- Rožňava, Slovakia
- Svidník, Slovakia
- Zlaté Moravce, Slovakia
- Barcelona, Spain
- Madrid, Spain
- Málaga, Spain
- Oviedo, Spain
- Zamora, Spain
- Dnipropetrovsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Vinnitsa, Ukraine
- Czechia
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is H. Lundbeck A/S.
Did this study involve medication?
Yes. The study involved medication, including Risperidone, Olanzapine and Lu AF35700.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.
